A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Sponsor

Tesaro, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT02048488

Collaborator

(none)

Enrollment

Locations

Arm

Duration (Months)

4.8

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including:

Anaplastic lymphoma kinase (ALK)
The tropomyosin-related kinases TRKA, TRKB, and TRKC

This is a sequential, open-label, non-randomized study with dose escalation in Phase 1, followed by expansion at a recommended phase 2 dose.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumors Lymphomas	Drug: TSR-011	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

72 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Study Start Date :

Oct 1, 2012

Actual Primary Completion Date :

Sep 1, 2016

Actual Study Completion Date :

Jun 1, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experimental Drug TSR-011 Experimental Drug TSR-011	Drug: TSR-011 Number of cycles until progression or unacceptable toxicity develops. Other Names: ALK inhibitor, ALKi TRK inhibitor

Arm

Intervention/Treatment

Experimental: Experimental Drug TSR-011

Experimental Drug TSR-011

Drug: TSR-011

Number of cycles until progression or unacceptable toxicity develops.

Other Names:

ALK inhibitor, ALKi

TRK inhibitor

Outcome Measures

Primary Outcome Measures

Incidence of Adverse Events (AEs) [Approximately 2 years]

Secondary Outcome Measures

Area Under the Concentration-Time Curve (AUC) [Day 1: 0-24 hrs after first dose; pre-dose on days 8 & 15; day 29: 0-24 hours]
Maximum Tolerated Dose (MTD) [28 days after first dose]
Phase 1, during the dose-escalation phase
Response Rate (RR) [approximately 2 years]
Phase 2
Dose limiting toxicity (DLT) [28 days after first dose]
Phase 1, during the dose escalation phase
Progression Free Survival (PFS) [approximately 2 years]
Phase 2
Recommended Phase 2 Dose (RP2D) [approximately 2 years]
Phase 1

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

To be considered eligible to participate in this study, all of the following requirements must be met:

Patients in Phase 1 must have metastatic or locally advanced solid tumors who have failed to respond to standard therapy
All patients must have confirmation of either ALK positive or TRK positive status.
Patients in Phase 1 will not be required to have measurable disease. All patients in Phase 2a will be required to have measurable disease by RECIST.
All patients enrolled in this study must have tumor tissue available.
Patient (male or female) must be ≥ 18 years of age (except where age of majority is 16 years in a particular country, such as the United Kingdom).
Patient must have performance status ≤2 on the ECOG Performance Scale.
Patient must have an estimated life expectancy of at least 3 months.
Patients must have adequate organ function.
For patients previously treated with myelosuppressive therapy, at least 3 weeks must have elapsed and toxicity must have recovered to grade 1 or baseline. Non-myelosuppressive therapy patients must have recovered from all treatment-related toxicities. Fourteen days must have elapsed since palliative radiation for bone metastasis.
Female patients of childbearing potential must have a negative serum pregnancy test and use adequate birth control for the duration of study participation and for 3 months after the last dose of study drug.
The patient or his or her legal representative must be able to read, understand, and provide signed informed consent.
Patient is able to understand the study procedures and agrees to participate in the study by giving written informed consent.

Exclusion Criteria:

Patients will not be deemed eligible for entry into this study if any of the following criteria are met:

Patient has leukemia.
Patient is a pregnant or lactating female.
Patient has uncontrolled congestive heart failure, angina, or has had a myocardial infarction in the preceding 3 months.
Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, atrial fibrillation of any grade, or QTc interval >450 msec.
Patients with risk factors for Torsade de point and patients receiving concomitant medication with QT-prolonging medicines.
Patient has an uncontrolled concurrent medical condition or disease.
Patient has undergone bone marrow or stem cell transplantation in the past 6 months.
Patient has a known hypersensitivity to the components of TSR-011 or the excipients.
Patient has active or uncontrolled infection.
Patient has a known psychiatric or substance abuse disorder.
Patient has active second primary malignancy.
Patient is observed to have a clinically active central nervous system (CNS) metastases or carcinomatous meningitis.
Patient has any other severe concurrent disease which, in the judgment of the Investigator, would preclude study participation.
Patient is known to be HIV positive or who has an AIDS-related illness.
Patient has a known history of or active (treated or not) Hepatitis B or C.
Patient has presence of ascites causing significant symptoms.
A patient must stop taking any prescription, over-the-counter, or herbal remedy known to be an inhibitor or inducer of CYP3A4/5.

Contacts and Locations

Locations

	City	State	Country
1	Goodyear	Arizona	United States
2	Scottsdale	Arizona	United States
3	Los Angeles	California	United States
4	Nashville	Tennessee	United States
5	Norfolk	Virginia	United States
6	Spokane	Washington	United States
7	Warsaw	Mazowieckie	Poland
8	Gdansk	Pomorskie	Poland
9	Olsztyn	Warminsko-Mazurskie	Poland
10	Poznan	Wielkopolskie	Poland
11	Madrid		Spain
12	Santiago de Compostela		Spain
13	Tainan City		Taiwan
14	Taipei		Taiwan
15	London		United Kingdom